Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms

TORONTO--(BUSINESS WIRE)-- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) provides a year-end business update on its commercialization progress across its three core areas of focus:

1. Nutraceuticals – Innovations through the Company’s Quicksome™ technology, designed to improve the administration and efficacy of nutraceutical health and wellness products;
2. Agriculture – The Company’s licensed Agrarius agricultural plant signaling technology, designed to organically drive increased crop yields, reduce fertilizer and pesticide usage where desired, and enhance plant health; and
3. Husbandry Animals and Aquatic Species – The application of solubilized drug formulations through the Company’s Quicksol™ technology, designed to positively impact the health of husbandry animals and aquatic species.

“Throughout 2025, we have remained focused on disciplined execution across each of our business lines,” said Dennis Hancock, President and CEO of Mountain Valley MD. “We believe the progress we have made in product development, field validation, and commercial foundations positions the Company for the next phase of measured growth.”

NUTRACEUTICALS

Quicksome™ Technology, Commercialization, and Business Development Progress

MVMD’s patented liposomal Quicksome™ technology uses proprietary formulations and stabilizing agents to encapsulate active ingredients with the goal of optimizing molecule delivery in sublingual nutraceutical applications. The Company’s Quicksome™ platform continues to focus on delivering molecules where enhanced efficacy, precise dosing, reduced variability, and dose sparing are valued.

“Our Quicksome™ technology continues to demonstrate to us its adaptability across multiple product formulations,” Mr. Hancock noted. “We believe the platform’s delivery characteristics and dose-sparing potential remain compelling for partners seeking differentiated products in competitive wellness categories.”

MVMD continues to advance its nutraceutical strategy through its exclusive manufacturing and licensing arrangement with a U.S.-based GMP production partner (the “Lead Manufacturer”), which maintains GMP and OTC drug manufacturing capabilities and has installed proprietary equipment to support Quicksome™ sublingual and dermal formulations.

The Lead Manufacturer continues to work with the Company to support production obligations under MVMD’s license agreement with Circadian Wellness Corp. (“Circadian”), as well as MVMD’s proprietary “Mountains Of…” product line and other business development initiatives. During 2025, scaled production and commercial activity continued for Circadian’s “Eons Dialed” and “Eons Deeper Sleep” sublingual products, both incorporating Quicksome™ technology. Circadian reported continued positive consumer reception and sales volumes of its Quicksome™-based products during the year.

In parallel, MVMD has continued business development initiatives to secure additional nutraceutical licensing partnerships through the development of novel formulation work for new clients in multiple human benefit areas including novel hot flash and night sweat symptoms relief in peri menopausal and post-menopausal women, post-workout muscle recovery, anti-inflammation, and joint health. The Company also remains engaged with a U.S.-based multi-level marketing client for a novel fenugreek glycosides testosterone formulation utilizing Quicksome™ quick-dissolve tablet technology. The formulation has supported documented performance in male subjects, and iterative product evaluations related to taste and dissolution have continued, with commercial discussions expected to advance as partner review processes progress. Additional client discussions have taken place in the fourth quarter and the Company expects the launch of a fenugreek glycosides testosterone formulation through a licensee in the first half of 2026.

The Company’s “Mountains Of…” proprietary brand continues to hold U.S. trademark protection across multiple product categories, including Sleep, Energy, Relief, Libido, and Lean, to support ongoing GMP sample development and business development activities. Distribution partners may elect to market MVMD’s branded products or pursue proprietary white-label versions under their own brands.

AGRICULTURE

Agrarius Business Development and Commercialization Progress

“We believe the continued validation of Agrarius across diverse crops and geographies reinforces its potential role in sustainable agricultural practices,” said Mr. Hancock. “Our focus remains on building a strong, data-driven foundation to support long-term commercial adoption.”

MVMD continues to advance commercialization in its agricultural division, which is focused on the licensed distribution of the Agrarius™ plant signaling technology. Under its exclusive license agreement with Agrarius Corp. (“AC”), MVMD holds the exclusive rights to sell the Agrarius product throughout North America, Central America, South America, and the Caribbean (the “Exclusive Territory”).

The Agrarius product is mixed with water or other agricultural inputs at the point of application and applied via sprayer at targeted stages of a plant’s lifecycle. Agrarius has been tested across numerous crops and has demonstrated its ability to naturally increase yields, improve plant resilience, and support reduced fertilizer usage, with results varying by crop and environment.

Brazil Citrus Trials, Including Positive Younger Tree Results

MVMD has been working with a client-directed third-party agricultural partner, FARMATAC, in Brazil to assess the impact of the application of the Agrarius product on both mature and young citrus orchards. FARMATAC has extensive experience designing and managing advanced citrus trials and has completed the contracted evaluations in commercial citrus orchards.

The Company previously reported the following results from mature Hamlin and Valencia orange trees:

• Hamlin Variety: Agrarius-treated orchards demonstrated improved plant condition and a productivity increase of approximately 15% per hectare. Juice yield analysis showed that the treated oranges required 20 fewer boxes to produce one ton of juice compared to the control, resulting in an approximate total yield increase of 22%. Independent agronomists also observed a visual reduction in symptoms associated with Huanglongbing (HLB), also known as citrus greening disease.
• Valencia Variety: The Agrarius-treated block achieved a 49% average yield increase. Treated trees also exhibited stronger vigor and canopy density, consistent with improved nutrient uptake and photosynthetic activity.

Building on the mature orchard results, newly completed trials on additional citrus blocks, including younger orchards and additional varietals at the client’s site, have now demonstrated further compelling outcomes. In trials that included treatments on younger trees, Agrarius-treated areas showed materially stronger plant vigor, improved flowering and fruit set, enhanced resilience to stress, including during periods of drier growing conditions, and significantly higher productivity when compared to control blocks. Notably, productivity gains of greater than 50 percent were recorded in Pera varietals, alongside results consistent with prior Hamlin and Valencia performance, reinforcing the potential lifecycle impact of Agrarius when applied earlier in orchard development and its potential role in helping mitigate yield variability under increasingly challenging climatic conditions.

“The Brazil citrus trial demonstrates to us that Agrarius™, under real farm conditions and third-party monitoring, delivered substantial yield improvements, stronger plant health, and meaningful mitigation of Greening stress in citrus,” continued Hancock. “Our agronomy team recently reviewed the trial results with the client’s leadership team and it is believed the findings will support commercial expansion in 2026, positioning Agrarius as a high-impact, low-disruption tool for Brazilian citriculture.”

The Company believes that the continued observation of reduced visible HLB symptoms across its Brazil citrus programs, including in younger orchards, represents one of the most meaningful indicators emerging from its citrus field work to date. These results are consistent with citrus trials previously reported by the Company and support the potential lifecycle relevance of Agrarius in orchards impacted by citrus greening disease.

“HLB has fundamentally altered citrus production in many regions, and producers still face the reality that there is no known cure,” said Hancock. “Seeing similar trends not only in mature trees but also in younger orchards strengthens our view that, if sustained, Agrarius could become an important organic tool to help growers manage greening pressure while building healthier, more productive orchards over time.”

Broad Crop Validation and LATAM Expansion

In addition to citrus, Agrarius trials conducted during the year across key crops in Brazil and Colombia in partnership with universities, private agronomy labs, and farmer networks continued to demonstrate to the Company positive outcomes, including:

• Corn – Yield gains of approximately 14.8 percent and 11.2 percent in UNESP trials, associated with improved chlorophyll concentration and root development.
• Sugarcane – Yield improvements of 8 to 12 tons per hectare, increased sugar content, and reduced pest damage in Agroquatro trials, alongside improved early development in seedling clone studies.
• Soybeans – Average yield gains of 6.34 sacs per hectare across 14 farmer validations, with high-performance producers achieving gains exceeding 15 percent.
• Cotton – Increases in bolls per plant and overall yield supported by improved photosynthetic efficiency.
• Potatoes – Productivity increases of approximately 18.5 percent in summer harvest trials.

Of particular note, during extended dry periods observed in Brazil field programs, Agrarius-treated crops experienced notably lower yield losses than untreated controls, supporting the product’s potential to improve water-use efficiency and maintain productivity under drought stress as part of an integrated agronomic program.

“The recent citrus trialing activity has produced results that reinforce what we are seeing across multiple crops in Brazil, that Agrarius is not only driving yield improvement, but also helping plants stay productive when conditions are less than ideal,” continued Hancock. “In markets where growers face increasing climate variability, this kind of resilience can be just as important as top-line yield gains.”

In Colombia, MVMD is completing its large-scale pasture grass productivity program in partnership with FEDEGAN, the national cattle growers’ federation representing approximately 43 million hectares of pastureland, and the National University of Colombia, with preliminary results demonstrating improved vegetation health, faster regrowth, and enhanced pasture quality, supported by satellite analysis and laboratory validation. Final results are expected in the first quarter of 2026.

HUSBANDRY ANIMALS / AQUATIC SPECIES

Soluvec™ 1% Commercialization Update and Strategic Review

MVMD has applied its patented Quicksol™ solubilization technology to ivermectin to create its Soluvec™ 1% formulation, which was designed to provide a safer and more effective solution for administration across husbandry animals and aquatic species. The Soluvec™ 1% formulation has demonstrated nine-month stability at room and refrigerated temperatures through third-party validation and remains the Company’s primary Quicksol™-based commercial asset.

The Company’s commercialization strategy for Soluvec™ 1% has been to advance the technology through third-party licensing. In Bangladesh, MVMD entered into an exclusive license agreement with an arm’s length, privately held partner to manufacture and distribute Soluvec™ 1% products in injectable and feed coating formats, in return for royalty payments based on net sales. As previously disclosed, the licensee has produced approximately 200 tonnes of Soluvec™ 1% coated fish feed and distributed product through local channels.

While this activity represented an important first step in demonstrating large-scale manufacturing and application of the Soluvec™ formulation, royalty revenues and overall commercial traction during 2025 have remained below management’s expectations. External market disruption, including impacts from Cyclone Remal in 2024, has affected industry conditions in the region, and MVMD continues to assess the most effective pathway to advance broader adoption of the technology.

“We continue to believe in the strength of the underlying science and formulation behind Soluvec™,” stated Hancock. “At the same time, we recognize that realizing its commercial potential requires partners with the right operational scale, market reach, and strategic alignment.”

As part of its assessment, the Company is undertaking a strategic review of its Soluvec™ 1% licensing structure, including evaluating options to modify or restructure territorial exclusivity in Bangladesh, subject to contractual rights and ongoing discussions between relevant parties. The objective is to ensure MVMD has the flexibility to work with partners best positioned to drive effective commercialization.

With a continued focus on disciplined capital allocation, MVMD intends to prioritize low-capital, royalty-based licensing opportunities for Soluvec™ 1% rather than direct investment in manufacturing or market buildout. In this context, management has initiated discussions with potential new licensees in Latin America, where demand for scalable and cost-effective husbandry and aquaculture health solutions remains significant and where the Company’s patent strategy supports future commercial development.

Global interest in Soluvec™ continues in management’s view, supported by the Company’s peer-reviewed data demonstrating improved bioavailability, efficacy, and stability relative to conventional ivermectin formulations. While the Company does not anticipate near-term material revenues until additional licensing arrangements are secured, MVMD believes that a more selective and partner-aligned approach can better position Soluvec™ for sustainable royalty growth over time.

“Soluvec™ remains an important asset for the Company, and we are working to align it with partners who can advance this opportunity effectively as we move into 2026,” Hancock added.

ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.
Mountain Valley MD is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations:

• patented Quicksome™ oral formulation and delivery technologies,
• patented Quicksol™ solubility formulation technology
• licensed product reseller of Agrarius™, a novel agricultural plant signaling technology

Consistent with its vision towards “More Life”, MVMD applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, MVMD’s work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage.

MVMD’s patented Quicksome™ technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy.

MVMD’s patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.

MVMD’s licensed Agrarius™ agricultural plant signaling technology is designed to be applied to crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change.

For more Company information and contact details, visit www.MVMD.com.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.

The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company.

The Company is making forward-looking statements, including but not limited to: the continued advancement of the Company’s lines of business; anticipated license arrangements and launches and the timing thereof with regard to the Company’s Quicksome™ technology; continued trials and anticipated results of the Company’s licensed Agrarius™ product and the timing thereof; and the securing of additional licensing arrangements, and the structure and timing thereof, regarding the Company’s Soluvec™ product.

The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

Neither the CSE nor OTC has reviewed or approved the contents of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251224207390/en/

Dennis Hancock

President and Chief Executive Officer

Mountain Valley MD Holdings Inc.

Investor Relations @ 647-725-9755

Email: info@mvmd.com

www.MVMD.com

Source: Mountain Valley MD Holdings Inc.